Kabir Mody

ORCID：0000-0003-3254-2990

发表论文 166 篇 · 总被引 6336 次 · h-index 33

代表论文

• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (2022 · NEJM Evidence · 被引 1540)
• Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022 · Journal of Clinical Oncology · 被引 406)
• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 347)
• The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer (2022 · Annals of Oncology · 被引 148)
• Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures (2022 · JCO Precision Oncology · 被引 72)
• A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma (2024 · Annals of Oncology · 被引 44)